# US 2022/0031636 A1 · Compounds that enhance the action of metformin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031636 A1
- Document ID: US20220031636A1
- Status: Published application
- Kind: A1
- Application number: 17/280,319
- Filed: 2019-09-25
- Published: 2022-02-03
- Earliest claimed: 2018-09-28
- Assignees: Societe des Produits Nestle S.A.
- Applicants: SOCIETE DES PRODUiTS NESTLE S.A.
- Inventors: Denis Marcel Barron; Nicolas Bonhoure; Yann Ratinaud; Kei Sakamoto; Matthew Sanders
- Web page: https://patentgrep.com/patent/US20220031636A1

## CPC

- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates in general to a medicament comprising Metformin or a salt thereof; and a compound having the general formula (I) or a salt thereof. The invention further relates to a pharmaceutical composition comprising the medicament for use in the prevention or treatment of a metabolic disease or a cardiovascular disease.

## Claims

### Claim 1

A medicament comprising
(i) Metformin; and
(ii) a compound having the general formula (I)
wherein, in compound (ii), R1, R2, R3, R4, R5, R6, R7, and R8 are each independently H; OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; and a sulfate.

### Claim 2 (depends on 1)

The medicament according to claim 1, wherein R1, R2, R3, R4, R7, and R8 are each independently H; OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; a sulfate; R5 is H; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; a sulfate; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; and a sulfate.

### Claim 3 (depends on 1)

The medicament according to claim 1, wherein R1, R2, R3, R4, R7, and R8 are each independently H; OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; a sulfate; R5 is H; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; a sulfate; R6 is H; OH; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; and a sulfate in compound (ii).

### Claim 4 (depends on 1)

The medicament according to claim 1, wherein R1, R3, and R8 are each independently H; OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; R2 is OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; R4 is H; OH; O-glycoside; a halogen; an aldehyde; a carboxylic acid; R5 is H; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; R6 is H; OH; O-glycoside; a halogen; an aldehyde; a carboxylic acid; and R7 is H; OH; O-glycoside; a halogen; an aldehyde; and a carboxylic acid in compound (ii).

### Claim 5 (depends on 1)

The medicament according to claim 1, wherein R1, R3, and R8 are each independently H; OH; OMe; R2 is OH; OMe; R4 is H; OH; R5 is H; OMe; R6 is H; OH; and R7 is H; and OH in compound (ii).

### Claim 6 (depends on 1)

The medicament according to claim 1, wherein R1, R3, R6 and R8 are each independently H; R2 is OH; OMe; R4 is OH; R5 is H; OMe; and R7 is H; and OH in compound (ii).

### Claim 7 (depends on 1)

The medicament according to claim 1, wherein compound (ii) is Lusianthridin (7-Methoxy-9,10-dihydrophenanthrene-2,5-diol, CAS number 87530-30-1) and has the formula

### Claim 8 (depends on 1)

The medicament according to claim 1, wherein Metformin or a salt thereof, and a compound of general formula (I), or a salt thereof are combined in a single preparation.

### Claim 9 (depends on 1)

The medicament according to claim 1, wherein Metformin or a salt thereof, and a compound of general formula (I), or a salt thereof are separately formulated into compositions and used in combination.

### Claim 10

A pharmaceutical composition comprising a medicament comprising
(i) Metformin; and
(ii) a compound having the general formula (I)
wherein, in compound (ii), R1, R2, R3, R4, R5, R6, R7, and R8 are each independently H; OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; and a sulfate, in a pharmaceutically acceptable form.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, for use in the prevention or treatment of a metabolic disease or a cardiovascular disease.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the metabolic disease is diabetes.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the prevention or treatment of diabetes is by increasing the inhibition of lipogenesis.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the prevention or treatment of diabetes is by increasing the inhibition of lipogenesis in liver cells and improving insulin sensitivity by activation of AMP-activated protein kinase (AMPK).

### Claim 15 (depends on 9)

The pharmaceutical composition according to claim 9, wherein metformin is used at a sub-pharmalogical dose for the subject.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the sub-pharmacological dose is not more than about 50% of the standard pharmacological dose for the subject.

### Claim 17 (depends on 14)

The pharmaceutical composition according to claim 14, wherein the subpharmacological dose of metformin reduces the incidence of side effects associated with metformin use, wherein the side effects are lactic acidosis, and/or gastro-intestinal side effects, particularly diarrhea, nausea, and vomiting.

### Claim 18

A method of preventing or treating a metabolic disease or a cardiovascular disease comprising the administration of a medicament comprising
(i) Metformin; and
(ii) a compound having the general formula (I)
wherein, in compound (ii), R1, R2, R3, R4, R5, R6, R7, and R8 are each independently H; OH; OMe; O-glycoside; a halogen; an aldehyde; a carboxylic acid; a primary, secondary, or tertiary amine; a primary or secondary amide; a cyano; a nitro; a sulfonate; and a sulfate to a subject in need thereof.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the disease is diabetes.
